A combined phase 1 and 2 clinical trial of Pfizer's mRNA flu and COVID-19 combination vaccine have yielded positive results, the company announced Oct. 26.
In the early trials, the vaccine showed efficacy in protection against influenza A, influenza B and COVID-19. Data also showed that the combination vaccine has a similar safety profile to Pfizer's normal COVID-19 shot.
"This vaccine has the potential to lessen the impact of two respiratory diseases with a single injection and may simplify immunization practices for providers, patients, and healthcare systems all over the world," said Annaliesa Anderson, PhD, senior vice president and the head of vaccine research and development at Pfizer.
The experimental shot will enter a phase 3 trial in a matter of months.